Company news
Zhejiang Huahai Pharmaceutical Co., Ltd. Class A (SSE:600521) news
Zhejiang Huahai Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Feb 28, 2026: Announcement on Progress in Legal Proceedings Involving…
Press releases — page 2
Announcement on Progress in Legal Proceedings Involving the Company and Its Subsidiaries
February 27, 2026
Announcement on Obtaining the Notice on Approval of Drug Supplement Application
February 3, 2026
Announcement on Expected Decrease in Performance for 2025
January 26, 2026
On-Site Inspection Report of Zheshang Securities Co., Ltd. on Continuous Supervision over ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. in 2025
January 5, 2026
Announcement on Release of Pledge of Partial Equity of Shareholder
December 31, 2025
Announcement on Optional Repurchase Results of "Huahai Convertible Bonds"
December 30, 2025
Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical Trial
December 26, 2025
Announcement on Progress in Drug Clinical Trials by Subsidiary
November 19, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 10, 2025
Announcement on the Subsidiary Passing On-site Inspection by FDA
November 6, 2025
Announcement on Not Revising Downward the Conversion Price of ""HUAHAI Convertible Bonds"
November 5, 2025
Report for Q3 2025
October 30, 2025
Announcement on Products Being Prospective Winners in the 11th National Centralized Drug Procurement
October 28, 2025